From the Department of Pediatric Intensive Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
the Department of Pediatric Intensive Care Unit, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):710-715. doi: 10.1097/MPG.0000000000003759. Epub 2023 Mar 12.
This study aimed to compare the efficacy of double plasma molecular adsorption system (DPMAS) with half-dose plasma exchange (PE) to that of full-dose PE in pediatric acute liver failure (PALF).
This multicenter, retrospective cohort study was conducted in 13 pediatric intensive care units in Shandong Province, China. DPMAS+PE and single PE therapies were performed in 28 and 50 cases, respectively. The patients' clinical information and biochemical data were obtained from the patients' medical records.
The severity of illness did not differ between the 2 groups. At 72 hours after treatment, comparing with PE group, the rates of decline of Pediatric model for End-stage Liver Disease and Pediatric Sequential Organ Failure Assessment scores as well as total bilirubin blood ammonia and interleukin-6 were significantly higher, while the short-term effective rate (75.0% vs 44.0%, P = 0.008) was significantly higher in the DPMAS+PE group. The volume of plasma consumption (26.5 vs 51.0 mL/kg, P = 0.000) and the rate of adverse events (3.6% vs 24.0%, P = 0.026) were lower in the DPMAS+PE group than in the PE group, respectively. However, there was no statistical difference in the 28-day mortality between the 2 groups (21.4% vs 40.0%, P > 0.05).
For PALF patients, both DPMAS + half-dose PE and full-dose PE could improve the liver function, while DPMAS + half-dose PE could significantly reduce plasma consumption without obvious adverse effects in contrast with full-dose PE. Thus, DPMAS + half-dose PE may be a suitable alternative method for PALF in the context of the increasingly tight blood supply situation.
本研究旨在比较双重血浆分子吸附系统(DPMAS)与半量血浆置换(PE)在儿科急性肝衰竭(PALF)中的疗效与全量 PE 的疗效。
本多中心回顾性队列研究在中国山东省的 13 个儿科重症监护病房进行。DPMAS+PE 和单一 PE 治疗分别在 28 例和 50 例患者中进行。患者的临床信息和生化数据从患者的病历中获得。
两组患者的疾病严重程度无差异。治疗后 72 小时,与 PE 组相比,DPMAS+PE 组的儿童终末期肝病模型(PELD)评分和小儿序贯器官衰竭评估(SOFA)评分下降率、总胆红素、血氨和白细胞介素-6 均显著更高,而短期有效率(75.0% vs. 44.0%,P = 0.008)显著更高。DPMAS+PE 组的血浆消耗量(26.5 vs. 51.0 mL/kg,P = 0.000)和不良事件发生率(3.6% vs. 24.0%,P = 0.026)均低于 PE 组。然而,两组 28 天死亡率无统计学差异(21.4% vs. 40.0%,P > 0.05)。
对于 PALF 患者,DPMAS+半量 PE 和全量 PE 均可改善肝功能,而与全量 PE 相比,DPMAS+半量 PE 可显著减少血浆消耗,且无明显不良反应。因此,在血液供应日益紧张的情况下,DPMAS+半量 PE 可能是 PALF 的一种合适替代方法。